Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.
AstraZeneca deepens UK-China ties with cell therapy R&D hub, manufacturing plans
AstraZeneca has added more details on how it will use its $15 billion budget to expand in China — and the UK pharma is betting



